DDInter1867 DDInter1082
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Triflupromazine {u} (Compound) binds {v} (Gene) DRD1
Triflupromazine {u} (Compound) upregulates {v} (Gene) SLC2A6
Triflupromazine {u} (Compound) downregulates {v} (Gene) ZDHHC6
Triflupromazine (Compound) resembles Pipotiazine (Compound)
Triflupromazine (Compound) resembles Desipramine (Compound)
Triflupromazine (Compound) binds DRD1 (Gene)
Triflupromazine (Compound) upregulates SLC2A6 (Gene)
Triflupromazine (Compound) downregulates ZDHHC6 (Gene)